HUTCHMED (CHINA) LIMIT

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

11 Apr 2023 20:00:00 By Nasdaq GlobeNewswire

Intended Retirement of Independent Non-executive Director

11 Apr 2023 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

04 Apr 2023 05:30:00 By Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

30 Mar 2023 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

14 Mar 2023 09:30:00 By Nasdaq GlobeNewswire

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

12 Mar 2023 20:07:31 By Nasdaq GlobeNewswire

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

28 Feb 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Final Results

31 Jan 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

23 Jan 2023 03:00:55 By Nasdaq GlobeNewswire

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

18 Jan 2023 09:30:00 By Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

03 Jan 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

19 Dec 2022 05:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

14 Nov 2022 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

13 Nov 2022 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

27 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

10 Oct 2022 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

07 Sep 2022 18:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

23 Aug 2022 04:30:00 By Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

09 Aug 2022 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

08 Aug 2022 06:01:59 By Nasdaq GlobeNewswire